{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:39:23Z","timestamp":1788986363837,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.diagmicrobio.2023.115945","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T06:54:22Z","timestamp":1679381662000},"page":"115945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018\u20132022)"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-6644","authenticated-orcid":false,"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Kimbrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia G.","family":"Carvalhaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.diagmicrobio.2023.115945_bib0001","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7326\/M16-0291","article-title":"Progress in the fight against multidrug-resistant bacteria? A review of U.S. Food and Drug Administration-approved antibiotics, 2010-2015","volume":"165","author":"Deak","year":"2016","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2023.115945_bib0002","doi-asserted-by":"crossref","first-page":"ofab141","DOI":"10.1093\/ofid\/ofab141","article-title":"Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae-producing KPC-31, a D179Y variant of KPC-3","volume":"8","author":"Tiseo","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2023.115945_bib0003","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2023.115945_bib0004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13054-020-2742-9","article-title":"Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae","volume":"24","author":"Falcone","year":"2020","journal-title":"Crit Care"},{"issue":"10","key":"10.1016\/j.diagmicrobio.2023.115945_bib0005","doi-asserted-by":"crossref","first-page":"ofaa378","DOI":"10.1093\/ofid\/ofaa378","article-title":"Clinical and microbiological analysis of risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia","volume":"7","author":"Son","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2023.115945_bib0006","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/14787210.2020.1756775","article-title":"Meropenem\/vaborbactam: a next generation beta-lactam beta-lactamase inhibitor co mbination","volume":"18","author":"Novelli","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2023.115945_bib0007","article-title":"New perspectives on antimicrobial agents: imipenem-relebactam","volume":"66","author":"O'Donnell","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2023.115945_bib0008","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s15010-022-01876-x","article-title":"Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negativebacteria infections","volume":"50","author":"Zhen","year":"2022","journal-title":"Infection"},{"issue":"Suppl 1","key":"10.1016\/j.diagmicrobio.2023.115945_bib0009","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/ofid\/ofy346","article-title":"The importance of antimicrobial resistance monitoring worldwide and the origins of SENTRY antimicrobial surveillance program","volume":"6","author":"Fuhrmeister","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2023.115945_bib0010","doi-asserted-by":"crossref","first-page":"e01587","DOI":"10.1128\/AAC.01587-18","article-title":"Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. Census Divisions: results from the 2017 INFORM Program","volume":"62","author":"Sader","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2023.115945_bib0011","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/ofid\/ofy346","article-title":"Global surveillance of antimicrobial resistance: 20 years of experience with the SENTRY program","volume":"6","author":"Fuhrmeister","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2023.115945_bib0012","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2023.115945_bib0013","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2023"},{"key":"10.1016\/j.diagmicrobio.2023.115945_bib0014","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2018"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2023.115945_bib0015","doi-asserted-by":"crossref","first-page":"dlac098","DOI":"10.1093\/jacamr\/dlac098","article-title":"Prevelance of carbapanemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime-avibactam and comparator agents","volume":"4","author":"Castanheira","year":"2022","journal-title":"JAC - Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2023.115945_bib0016","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/cid\/cir202","article-title":"Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention","volume":"53","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2023.115945_bib0017","first-page":"165","article-title":"Vital signs: carbapenem-resistant enterobacteriaceae","volume":"62","author":"Jacob","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2023.115945_bib0018","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","article-title":"Interplay between beta-lactamases and new beta-lactamase inhibitors","volume":"17","author":"Bush","year":"2019","journal-title":"Nat Rev Microbiol"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2023.115945_bib0019","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","article-title":"Novel beta-lactamase inhibitors: Unlocking their potential in therapy","volume":"77","author":"Wong","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.diagmicrobio.2023.115945_bib0020","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.2147\/IDR.S224228","article-title":"A clinical review and critical evaluation of imipenem-relebactam: evidence to date","volume":"13","author":"Campanella","year":"2020","journal-title":"Infect Drug Resist"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2023.115945_bib0021","first-page":"e00642","article-title":"Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant enterobacteriaceae","volume":"61","author":"Haider","year":"2017","journal-title":"Antimicro Agents Chemother"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2023.115945_bib0022","doi-asserted-by":"crossref","first-page":"e00672","DOI":"10.1128\/AAC.00672-19","article-title":"Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae","volume":"63","author":"Canver","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2023.115945_bib0023","first-page":"48","volume":"127","author":"Lee","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2023.115945_bib0024","doi-asserted-by":"crossref","first-page":"ofad046","DOI":"10.1093\/ofid\/ofad046","article-title":"Changing epidemiology of carbapenemases among carbapenem-resistant enterobacterales from United States hospitals and the activity of aztreonam-avibactam against contemporary enterobacterales (2019\u20132021)","volume":"10","author":"Sader","year":"2023","journal-title":"Open Forum Infect Dis"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288932300055X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288932300055X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:58:36Z","timestamp":1760003916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073288932300055X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S073288932300055X"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2023.115945","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018\u20132022)","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2023.115945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115945"}}